BioMérieux BIOFIRE Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Becomes First COVID-19 Diagnostic Test to Obtain De Novo FDA Authorization
|
By HospiMedica International staff writers Posted on 19 Mar 2021 |
|
Image: BIOFIRE RP2.1 Panel (Photo courtesy of BioMérieux)
BioMérieux (Marcy-l'Étoile, France) has received US Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE RP2.1 Panel, making it the first SARS-CoV-2 diagnostic test of any kind to be granted De Novo status by US FDA.
The panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel was granted De Novo status by US FDA after having gone through the normal US FDA review pathway outside of the Emergency Use Authorization (EUA) track. The De Novo authorization will be concurrent with the revocation of the US FDA EUA that was obtained on May 1, 2020 for the panel. The BIOFIRE RP2.1 Panel EUA and De Novo kits are identical with the exception of changes to the labeling.
The BIOFIRE RP2.1 Panel allows healthcare providers to quickly identify common respiratory pathogens found in patients presenting with acute respiratory tract infection, using one simple test. The BIOFIRE RP2.1 Panel yields results in approximately 45 minutes using nasopharyngeal swab (NPS) samples in transport media or saline. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE Torch Systems with only two minutes of sample preparation time.
The De Novo application was supported by a multicenter prospective clinical study in which the performance of the BIOFIRE RP2.1 Panel SARS-CoV-2 assay was evaluated in over 500 specimens against a combined reference of three independent molecular SARS-CoV-2 assays, each with U.S. FDA EUA designation. The BIOFIRE RP2.1 Panel SARS-CoV-2 assay demonstrated positive percent agreement (PPA) of 98.4% and negative percent agreement (NPA) of 98.9%.
“The De Novo authorization of the BIOFIRE RP2.1 Panel demonstrates how BioFire is dedicated to responding to a rapidly-evolving global pandemic with urgency and accuracy. This is the first US FDA De Novo authorized COVID-19 test,” said Pierre Boulud, Chief Operating Officer, Clinical Operations of bioMérieux.
Related Links:
BioMérieux
The panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel was granted De Novo status by US FDA after having gone through the normal US FDA review pathway outside of the Emergency Use Authorization (EUA) track. The De Novo authorization will be concurrent with the revocation of the US FDA EUA that was obtained on May 1, 2020 for the panel. The BIOFIRE RP2.1 Panel EUA and De Novo kits are identical with the exception of changes to the labeling.
The BIOFIRE RP2.1 Panel allows healthcare providers to quickly identify common respiratory pathogens found in patients presenting with acute respiratory tract infection, using one simple test. The BIOFIRE RP2.1 Panel yields results in approximately 45 minutes using nasopharyngeal swab (NPS) samples in transport media or saline. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE Torch Systems with only two minutes of sample preparation time.
The De Novo application was supported by a multicenter prospective clinical study in which the performance of the BIOFIRE RP2.1 Panel SARS-CoV-2 assay was evaluated in over 500 specimens against a combined reference of three independent molecular SARS-CoV-2 assays, each with U.S. FDA EUA designation. The BIOFIRE RP2.1 Panel SARS-CoV-2 assay demonstrated positive percent agreement (PPA) of 98.4% and negative percent agreement (NPA) of 98.9%.
“The De Novo authorization of the BIOFIRE RP2.1 Panel demonstrates how BioFire is dedicated to responding to a rapidly-evolving global pandemic with urgency and accuracy. This is the first US FDA De Novo authorized COVID-19 test,” said Pierre Boulud, Chief Operating Officer, Clinical Operations of bioMérieux.
Related Links:
BioMérieux
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Rapid Sepsis Test
SeptiCyte RAPID
Patient Monitoring System
AlarmSense
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
AI Tool Predicts Post-Heart Attack Trajectories to Personalize Follow-Up
Acute myocardial infarction (heart attack) survivors often develop new comorbidities and complications that unfold over years. Predicting which patients will deteriorate and where problems will arise remains... Read more
AI Digital Twin Platform Supports Personalized Cancer Treatment
Oncology teams face persistent challenges in tailoring treatment plans as tumors evolve and responses vary across patients. Static snapshots from imaging or genomics offer limited guidance for complex... Read more
Study Reveals Persistent Race and Gender Bias in Medical AI Models
Hospitals are turning to artificial intelligence (AI) to draft clinical materials and support decision-making, yet algorithmic bias can entrench inequities in care. When generated content reflects racial... Read more
New Study Highlights Benefits and Risks of AI Explanations in Clinical Diagnosis
Explainable artificial intelligence is increasingly used in tools that help clinicians and patients assess skin disease, but its explanations can influence decisions and contribute to overreliance or error.... Read moreCritical Care
view channel
Ultrasound Technique Enables Arrhythmia Risk Assessment in Mitral Valve Disease
Sudden cardiac death can occur when dangerous arrhythmias go undetected. Mitral valve prolapse and mitral regurgitation affect an estimated 2–5% of the population and have been linked to such events as... Read more
3D-Printed Membrane Could Enable Smaller, More Efficient Artificial Lungs
For patients with advanced lung disease, durable respiratory support is limited and donor organs are scarce. Extracorporeal membrane oxygenation (ECMO) can bridge failure, but current oxygenator membranes... Read more
Surgical Techniques
view channel
New Implant-Based System Gains FDA Approval for GERD Treatment
Gastroesophageal reflux disease is often treated surgically with techniques that encircle the esophagus, a strategy associated with dysphagia, inability to belch or vomit, and gas bloating.... Read more
Heartbeat-Powered Pacemaker Could Eliminate Battery Replacement Surgery
Pacemaker replacement surgeries expose patients to repeated procedural risks and added costs, particularly with leadless intracardiac systems that are difficult to explant once batteries deplete.... Read more
3D Bioprinting Method Enhances Bone Repair by Promoting Blood Vessel Growth
Severe bone loss after trauma, cancer, or infection is difficult to reconstruct because engineered grafts often fail to form stable blood vessels. Poor vascularization limits nutrient delivery, slows healing,... Read more
New Robotic Bronchoscopy Software Enhances Lung Nodule Navigation and Targeting
Accurate bronchoscopy to lung nodules can be technically challenging because patient anatomy may shift between pre-procedure computed tomography and the live procedure. These changes, together with CT-to-body... Read morePatient Care
view channel
Multicenter Study Quantifies Delays in Care for Emergency Department Boarders
Emergency department (ED) boarding—the practice of keeping admitted patients in the ED while awaiting an inpatient bed—creates hazardous delays in definitive care. Prolonged transitions expose older and... Read more
Real-Time Radiation Monitor Supports Safer Fluoroscopy-Guided Procedures
Fluoroscopy-guided procedures expose clinicians to scatter radiation that accumulates over time, creating persistent occupational risks in cath labs and interventional suites. Traditional badges typically... Read more
Medical Imaging
view channel
AI-Derived Brain Age from MRI Predicts Future Dementia Risk
Early identification of patients likely to progress to dementia remains difficult in memory clinics, where visual ratings of brain atrophy may miss subtle early changes. Dementia develops gradually and... Read more
Imaging Biomarkers Aim to Personalize Treatment for Post-Stroke Bladder Dysfunction
Post-stroke lower urinary tract dysfunction, including urinary incontinence, affects many stroke survivors and can persist long after the acute event. These symptoms undermine independence, burden caregivers,... Read more
Health IT
view channel
Imaging Tool Quantifies Calcinosis Cutis Volume to Monitor Treatment
Calcinosis cutis involves calcium deposits in the skin or soft tissues that can develop anywhere in the body, causing pain, impaired mobility, and disability. Lesions along the spine or buttocks can make... Read more
Digital Symptom Monitoring Supports More Personalized Breast Cancer Care
Metastatic breast cancer, in which tumors spread to other organs, is incurable but increasingly managed with modern systemic therapies. As more treatments shift from hospital infusions to oral or at-home... Read more
Point of Care
view channel
Ultrathin Metasurface Could Bring Quantitative Phase Imaging to Portable Devices
Point-of-care imaging often depends on bulky optical systems that have difficulty visualizing nearly transparent cells and tissues without staining. These limitations can slow diagnosis and restrict use... Read more
Rapid Onsite Testing Reduces Emergency Department Transfers in Long-Term Care
Respiratory infections in long-term care residents frequently trigger emergency department transfers that strain hospital capacity and expose frail patients to additional risks. Turnaround delays from... Read more
Business
view channel
Teledyne to Acquire Varex Imaging in $1.1 Billion Deal
Teledyne Technologies and Varex Imaging Corporation announced a definitive agreement on August 10, 2026, under which Teledyne will acquire all outstanding common shares of Varex for USD 18.... Read more
